Direkt zum Inhalt
Merck

Fortfahren mit

SML4475

Ponatinib hydrochloride

≥98% (HPLC)

Synonym(e):

3-(Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide Hydrochloride, AP24534 HCl, Ponatinib HCl

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
Größe/SKUVerfügbarkeitPreis

Über diesen Artikel

Empirische Formel (Hill-System):
C29H27F3N6O · xHCl
Molekulargewicht:
532.56 (free base basis)
UNSPSC Code:
12352200
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


Quality Segment

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

-10 to -25°C

Biochem/physiol Actions

AP24534 (Ponatinib) is a reversible, ATP-competitive, BBB-permeable and orally active pan-BCR-ABL inhibitor engineered to overcome multidrug-resistant CML. Its design features a rigid ethynyl linker that bypasses the steric hindrance of the T315I "gatekeeper" mutation, yielding profound potency against native ABL (IC50 0.37 nM), T315I (IC50 2.0 nM), and T315I-inclusive compound mutants (IC50 0.30–0.44 nM). This efficacy extends to cellular models, where it suppresses CrkL phosphorylation and inhibits proliferation in native (IC50 0.5 nM) and T315I-expressing (IC50 11 nM) cells. Beyond ABL, Ponatinib acts as a multi-kinase inhibitor modulating angiogenesis and stromal signaling, with high affinity for LYN (0.24 nM), PDGFRα (1.1 nM), VEGFR2 (1.5 nM), FGFR1-4 (~2.2 nM), SRC (5.4 nM), KIT (~12.5 nM), and FLT3 (~13 nM). Mechanistically, it halts STAT5, ERK, and AKT signaling to trigger cell cycle arrest and intrinsic apoptosis—driven by caspase-3 cleavage and Bcl-xL/Mcl-1 downregulation—or RIPK1/3-mediated necroptosis. To deepen molecular response against complex resistance, Ponatinib demonstrates significant synergy with MDM2 inhibitors, the allosteric inhibitor asciminib, and the BCL-2 inhibitor venetoclax.

Disclaimer

Hygroscopic, Store with desiccant

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
SML307615004911012775
description

≥98% (HPLC)

description

≥98% (HPLC)

description

United States Pharmacopeia (USP) Reference Standard

description

United States Pharmacopeia (USP) Reference Standard

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

-

assay

-

form

powder

form

powder

form

-

form

-

Quality Level

100

Quality Level

100

Quality Level

-

Quality Level

-

storage temp.

-10 to -25°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-30°C

solubility

DMSO: 2 mg/mL, clear (warmed)

solubility

DMSO: 2 mg/mL, clear

solubility

-

solubility

-

storage condition

desiccated

storage condition

desiccated

storage condition

-

storage condition

-


Hazard Classifications

Acute Tox. 3 Oral - Repr. 2 - STOT RE 1 Dermal

Zielorgane

Liver,Bone marrow,Pancreas,Cardio-vascular system

Lagerklasse

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Piktogramme

Skull and crossbonesHealth hazard

Signalwort

Danger

Gefahrencodes



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen